What does the instructions for Rozelixizumab contain?

Rozanolixizumab (Rozanolixizumab), trade name: RYSTIGGO, is an innovative humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn). It was developed by UCB Pharmaceuticals and is mainly used to treat adult myasthenia gravis (generalized Myasthenia). Gravis, gMG), especially those patients who are anti-acetylcholine receptor antibody (AChR-Ab) positive or anti-muscle-specific tyrosine kinase antibody (MuSK-Ab) positive. The drug is one of the first drugs approved for treatment by targeting FcRn receptors via subcutaneous injection, and is revolutionary in the treatment of immune-mediated neuromuscular diseases.

1. Mechanism of action and drug classification

Rozelixizumab specifically binds toFcRn receptor and blocks the recycling of IgG antibodies by the receptor, thereby reducing the concentration of pathogenic IgG antibodies in the body. Under normal circumstances, FcRn can prevent IgG from being catabolized and maintain its stable level in plasma. However, in some autoimmune diseases, abnormally elevated autoantibodies (such as anti-AChR, MuSK, etc.) in the body attack neuromuscular junctions, causing symptoms of muscle weakness. By inhibiting this recycling mechanism, roselixizumab causes pathogenic IgG antibodies to be quickly cleared and effectively alleviates disease progression. Due to its regulatory effect on immunoglobulin-specific metabolic pathways, roselixizumab is also regarded as one of the benchmark drugs in the field of FcRn inhibitors.

2. Indications and clinically applicable groups

Rozelixizumab is approved for the treatment of adult patients with confirmed systemic myasthenia gravis and the presence of anti-AChR or anti-MuSK antibodies. For patients who have poor response or poor tolerance to traditional treatments (such as glucocorticoids, intravenous immunoglobulin IGIV, or immunosuppressants), roselixizumab provides a treatment option with a new mechanism, especially suitable for individuals with high disease activity and high relapse frequency.

3. Dosage and administration method

Rozelixizumab is administered as a subcutaneous infusion once a week, with a continuous treatment course of 6 weeks . The dose is accurately calculated based on the patient's weight:

For patients weighing less than50kg, the dose is 420mg (infusion volume 3ml);

For those weighing between 50kg and 100kg, the dose is 560mg (infusion volume 4ml);

For those weighing 100kg and above, the dose is 840mg (infusion volume 6ml);

Usage is limited to subcutaneous injection, and it is recommended to use an infusion pump to inject slowly, with the infusion rate not exceeding 20ml per hour. This infusion method is different from traditional intravenous injection, has better patient tolerance, and is easy to complete under outpatient or home care conditions, significantly improving compliance and treatment convenience.

4. Administration time and treatment of missed doses

If the patient fails to take the medication on time within the specified time, a replacement infusion can be performed within 4 days after the scheduled time, but this time window must not be exceeded. If the medication is not replenished for more than 4 days, the medication should be continued from the original dose and schedule to complete the complete course of treatment. It is not recommended to extend or advance the next cycle at will. After each treatment cycle, doctors should judge whether to start a new cycle based on clinical assessment (such as myasthenia scores, changes in IgG levels). There is currently no clear evidence to support the safety of starting a new cycle within 63 days of the previous treatment, so such decisions need to be made with caution.

5. Vaccination and immune monitoring

Because roselixizumabacts on theIgG metabolism channel in the immune system, it may theoretically weaken the immune response to certain vaccines, especially the protective efficacy of live attenuated vaccines. Therefore, the labeling recommends that all age-appropriate vaccination schedules be evaluated and completed before initiating treatment with roselixizumab, particularly influenza, pneumococcal, and herpes zoster vaccines. In addition, for those with complicated past infection histories, attention should be paid to screening for potential chronic infection states, such as tuberculosis, hepatitis B, etc.

Reference materials:https://www.drugs.com/rystiggo.html